A detailed history of Bank Of America Corp transactions in Argenx Se stock. As of the latest transaction made, Bank Of America Corp holds 290,201 shares of ARGX stock, worth $171 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
290,201
Previous 273,556 6.08%
Holding current value
$171 Million
Previous $108 Million 15.87%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $5.93 Million - $7.52 Million
16,645 Added 6.08%
290,201 $125 Million
Q1 2024

May 15, 2024

BUY
$356.95 - $413.29 $48.2 Million - $55.8 Million
134,905 Added 97.3%
273,556 $108 Million
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $22.1 Million - $33 Million
-65,209 Reduced 31.99%
138,651 $52.7 Million
Q2 2023

Aug 14, 2023

SELL
$360.14 - $422.58 $33.8 Million - $39.7 Million
-93,972 Reduced 31.55%
203,860 $79.5 Million
Q1 2023

May 12, 2023

BUY
$334.23 - $403.65 $64.6 Million - $78 Million
193,353 Added 185.06%
297,832 $111 Million
Q4 2022

Feb 10, 2023

BUY
$342.17 - $402.31 $11.9 Million - $13.9 Million
34,655 Added 49.63%
104,479 $39.6 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $3.95 Million - $4.56 Million
-11,516 Reduced 14.16%
69,824 $24.7 Million
Q2 2022

Aug 12, 2022

BUY
$269.58 - $378.88 $841,898 - $1.18 Million
3,123 Added 3.99%
81,340 $30.8 Million
Q1 2022

May 16, 2022

BUY
$254.45 - $351.06 $6.93 Million - $9.56 Million
27,240 Added 53.44%
78,217 $24.7 Million
Q4 2021

Feb 08, 2022

SELL
$272.01 - $353.03 $24,480 - $31,772
-90 Reduced 0.18%
50,977 $17.9 Million
Q3 2021

Nov 15, 2021

SELL
$295.0 - $350.58 $407,690 - $484,501
-1,382 Reduced 2.63%
51,067 $15.4 Million
Q2 2021

Sep 13, 2021

BUY
$257.11 - $319.92 $13.5 Million - $16.8 Million
52,449 New
52,449 $15.8 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $32.6B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.